Ouro Medicines Announces Initiation of OM336 Basket Study in Autoimmune Cytopenias and Granting of U.S. FDA Orphan Drug Designation for OM336 in Autoimmune Hemolytic Anemia (AIHA)
Sites in the U.S. and Australia are participating in this Phase 1b study of OM336 in autoimmune cytopenias Initial results expected in 2026 Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated diseases, today announced the initiation of a multi-national clinical study of OM336, a BCMAxCD3 T cell engager […]